EA200100451A1 - Замещенные аналоги бензопирана для лечения воспаления - Google Patents

Замещенные аналоги бензопирана для лечения воспаления

Info

Publication number
EA200100451A1
EA200100451A1 EA200100451A EA200100451A EA200100451A1 EA 200100451 A1 EA200100451 A1 EA 200100451A1 EA 200100451 A EA200100451 A EA 200100451A EA 200100451 A EA200100451 A EA 200100451A EA 200100451 A1 EA200100451 A1 EA 200100451A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogues
treatment
benzopirane
inflammation
replaced
Prior art date
Application number
EA200100451A
Other languages
English (en)
Other versions
EA005599B1 (ru
Inventor
Джеффери С. Картер
Балекудру Девадас
Джон Дж. Талли
Дейвид Л. Браун
Меттью Дж. Грането
Дональд Дж. мл. Роджир
Шринивасан Р. Нагараян
Кэтлин Э. Хано
Сьюзен Дж. Хартманн
Синди Л. Людвиг
Сьюзен Мец
Дональд Э. Корт
Стивен Р. Бертеншо
Марк Г. Обуковиц
Original Assignee
Дж.Д.Сирл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200100451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дж.Д.Сирл Энд Ко. filed Critical Дж.Д.Сирл Энд Ко.
Publication of EA200100451A1 publication Critical patent/EA200100451A1/ru
Publication of EA005599B1 publication Critical patent/EA005599B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Приведено описание класса бензопиранов, бензотиопиранов, дигидрохинолинов, дигидронафталинов и их аналогов для использования при лечении расстройств, опосредованных циклооксигеназой-2. Соединения, представляющие особый интерес, определяются формулой (I'), где X, A, A, A, A, R, R", Rи Rсоответствуют представленному в описании.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100451A 1998-10-20 1999-10-15 Замещенные аналоги бензопирана EA005599B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/175,584 US6077850A (en) 1997-04-21 1998-10-20 Substituted benzopyran analogs for the treatment of inflammation
PCT/US1999/021460 WO2000023433A1 (en) 1998-04-17 1999-10-15 Substituted benzopyran analogs for the treatment of inflammation

Publications (2)

Publication Number Publication Date
EA200100451A1 true EA200100451A1 (ru) 2001-10-22
EA005599B1 EA005599B1 (ru) 2005-04-28

Family

ID=22640811

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100451A EA005599B1 (ru) 1998-10-20 1999-10-15 Замещенные аналоги бензопирана

Country Status (33)

Country Link
US (4) US6077850A (ru)
EP (1) EP1123285A1 (ru)
JP (1) JP2002527512A (ru)
KR (1) KR20010086438A (ru)
CN (1) CN1150181C (ru)
AP (1) AP2001002143A0 (ru)
AR (1) AR024839A1 (ru)
AU (1) AU767655C (ru)
BG (1) BG105513A (ru)
BR (1) BR9914696A (ru)
CA (1) CA2347910A1 (ru)
CU (1) CU23029A3 (ru)
CZ (1) CZ20011424A3 (ru)
EA (1) EA005599B1 (ru)
EE (1) EE200100227A (ru)
GE (1) GEP20033027B (ru)
HK (1) HK1040397B (ru)
HR (1) HRP20010288A2 (ru)
HU (1) HUP0104316A3 (ru)
ID (1) ID30062A (ru)
IL (1) IL142667A0 (ru)
IS (1) IS5921A (ru)
MY (1) MY138238A (ru)
NO (1) NO20011940L (ru)
NZ (1) NZ511593A (ru)
OA (1) OA11912A (ru)
PL (1) PL347384A1 (ru)
SK (1) SK5412001A3 (ru)
TR (1) TR200101969T2 (ru)
TW (1) TWI250979B (ru)
UA (1) UA75328C2 (ru)
WO (1) WO2000023433A1 (ru)
ZA (1) ZA200103200B (ru)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2247451C (en) * 1996-03-18 2006-01-03 Eisai Co., Ltd. Carboxylic acid derivatives having fused rings as retinoic acid receptor agonist
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
WO2001049675A1 (en) * 2000-01-03 2001-07-12 Pharmacia Corporation Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AU2001277560A1 (en) 2000-08-09 2002-02-18 F. Hoffmann-La Roche Ag Quinolene derivatives as anti-inflammation agents
EP1365753A2 (en) * 2001-02-02 2003-12-03 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
EP1363669A2 (en) * 2001-02-02 2003-11-26 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
AU2002306868A1 (en) * 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030236308A1 (en) * 2001-09-18 2003-12-25 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US20030114483A1 (en) * 2001-09-18 2003-06-19 Pharmacia Corporation Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
MXPA04002855A (es) 2001-09-25 2004-07-05 Pharmacia Corp Proceso para producir pirazoles sustituidos.
US7057049B2 (en) * 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
EP1463500A1 (en) * 2002-01-10 2004-10-06 PHARMACIA & UPJOHN COMPANY Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
EP1505962A2 (en) * 2002-04-18 2005-02-16 Pharmacia Corporation Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
MXPA05000259A (es) * 2002-07-02 2005-04-11 Pharmacia Corp Uso de inhibidores selectivos de ciclooxigenasa-2 y agentes tromboliticos para el tratamiento o prevencion de un evento vaso-oclusivo.
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
AU2003297397A1 (en) * 2002-12-19 2004-07-14 Pharmacia Corp Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
US20040171664A1 (en) * 2002-12-20 2004-09-02 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US20040176378A1 (en) * 2003-02-12 2004-09-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
WO2004093811A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
WO2004093896A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
CA2519189C (en) 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
WO2004100895A2 (en) * 2003-05-13 2004-11-25 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004103283A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2004103286A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
US20050113376A1 (en) * 2003-05-27 2005-05-26 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050054646A1 (en) * 2003-06-09 2005-03-10 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
JP2007522084A (ja) * 2003-06-24 2007-08-09 ファルマシア・コーポレーション 悪心を伴う片頭痛の治療
US20050042291A1 (en) * 2003-07-01 2005-02-24 Michael Hawley Diffusion layer modulated solids
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
US20050080083A1 (en) * 2003-07-10 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
WO2005018541A2 (en) * 2003-07-11 2005-03-03 Pharmacia Corporation Cox-2 inhibitor and serotonin modulator for treating cns damage
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
MXPA06002112A (es) * 2003-08-22 2006-05-17 Pharmacia Corp Composiciones de un inhibidor selectivo de ciclooxigenasa-2 y un agente modulador de serotonina para el tratamiento de neoplasia.
WO2005018564A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2005020910A2 (en) * 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
BRPI0414956A (pt) * 2003-10-03 2006-11-14 Pharmacia Corp composições de um inibidor seletivo da ciclooxigenase-2 administradas sob condições hipotérmicas para o tratamento de distúrbios ou lesões do sistema nervoso central mediados por isquemia
BRPI0415939A (pt) * 2003-11-12 2007-01-02 Pharmacia & Upjohn Co Llc composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
JP2007534740A (ja) * 2004-04-28 2007-11-29 ファイザー・インク バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
CA2573547A1 (en) * 2004-07-23 2006-02-02 Warner-Lambert Company Llc Photoracemization of 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
WO2006011052A1 (en) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
JP2008507502A (ja) * 2004-07-23 2008-03-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換２−トリフルオロメチル−２ｈ−クロメン−３−カルボン酸誘導体を分離するためのエナンチオ選択的方法
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006040672A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
WO2006040676A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
WO2006070984A1 (en) * 2004-12-31 2006-07-06 Sk Chemicals, Co., Ltd. Novel benzopyran derivatives having inhibitory activities against liver fibrosis and cirrhosis and their pharmaceutical uses
KR101135574B1 (ko) 2004-12-31 2012-04-23 한국화학연구원 간섬유화 및 간경화 억제 활성을 나타내는ν-(2,2-이중치환-2η-크로멘-6-일)싸이오우레아 유도체
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
WO2008072801A1 (en) * 2006-12-13 2008-06-19 Seoul National University Industry Foundation Compounds with embedded benzopyran motif for core structures and preparation method thereof
ATE511860T1 (de) 2006-12-22 2011-06-15 Recordati Ireland Ltd Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
AU2009282315A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. N-heterocyclic M1 receptor positive allosteric modulators
EP2326306A1 (en) * 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
BRPI1004922A2 (pt) * 2009-01-15 2019-09-24 Cephalon Inc composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
KR101292188B1 (ko) * 2009-03-27 2013-08-02 한국생명공학연구원 벤조피란 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN103889414A (zh) * 2011-10-18 2014-06-25 拉夸里亚创药株式会社 药物组合物
CN102757417B (zh) * 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
CN103044477B (zh) * 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
WO2020153279A1 (en) * 2019-01-22 2020-07-30 Askat Inc. Process for the differential solubility-driven asymmetric transformation of substituted 2h-chromene-3-carboxylic acids
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
WO2023183406A1 (en) * 2022-03-22 2023-09-28 Regents Of The University Of Minnesota Therapeutic compound and salts
CN117384091B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类酰胺衍生物、合成方法及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046778A (en) * 1975-08-13 1977-09-06 Warner-Lambert Company Processes for the preparation of 4-hydroxy-2H-1-benzothiopyran-3-carboxamide 1,1-dioxides
JPH0232279B2 (ja) * 1982-08-12 1990-07-19 Kowa Co Jihidorobenzopiranjioorunoseiho
US4609744A (en) * 1983-04-21 1986-09-02 Merck Frosst Canada Inc. 4-oxo-benzopyran carboxylic acids
GB8323293D0 (en) * 1983-08-31 1983-10-05 Zyma Sa Substituted flavene and thioflavene derivatives
US4761425A (en) * 1983-12-27 1988-08-02 Merck Frosst Canada, Inc. Leukotriene antagonists
US4761424A (en) * 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
JP2802996B2 (ja) * 1988-07-11 1998-09-24 興和株式会社 光学活性化合物の製造法
US5004744A (en) * 1988-12-13 1991-04-02 Bayer Aktiengesellschaft Pyridazinones as pesticides
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
EP0412939A3 (en) * 1989-08-11 1991-09-04 Ciba-Geigy Ag Certain benzopyran and benzothiopyran derivatives
US5155130A (en) * 1989-08-11 1992-10-13 Ciba-Geigy Corporation Certain benzopyran and benzothiopyran derivatives
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5281720A (en) * 1991-02-28 1994-01-25 Merck Frosst Canada, Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
JP3283114B2 (ja) * 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
IS4164A (is) * 1993-06-11 1994-12-12 Ab Astra Efnasambönd sem hindra flæði magasýru
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
PT804419E (pt) * 1994-05-27 2003-12-31 Smithkline Beecham Farma Derivados de quinolina como antagonistas do receptor de taquiquinina nk3
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
ES2193252T3 (es) * 1995-08-02 2003-11-01 Darwin Discovery Ltd Quinolonas y su uso terapeutico.
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
ATE223902T1 (de) * 1995-10-19 2002-09-15 Takeda Chemical Industries Ltd Chinolinderivate als gnrh antagonisten
DE19613591A1 (de) * 1996-04-04 1997-10-09 Hoechst Ag Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE240950T1 (de) * 1996-06-07 2003-06-15 Univ Vanderbilt Dihydrobenzopyran und ähnliche verbindungen verwendbar als antientzündungsmittel
JP3076066B2 (ja) * 1996-08-27 2000-08-14 塩野義製薬株式会社 クロメン−３−カルボン酸誘導体
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
EP0977989A1 (en) * 1997-02-04 2000-02-09 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
DE19755480A1 (de) * 1997-12-13 1999-06-24 Gruenenthal Gmbh Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
IL143870A0 (en) * 1998-12-23 2002-04-21 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Also Published As

Publication number Publication date
ZA200103200B (en) 2002-05-07
US6271253B1 (en) 2001-08-07
CA2347910A1 (en) 2000-04-27
TWI250979B (en) 2006-03-11
EE200100227A (et) 2002-10-15
UA75328C2 (en) 2006-04-17
HRP20010288A2 (en) 2002-06-30
AP2001002143A0 (en) 2001-04-15
CU23029A3 (es) 2005-02-23
PL347384A1 (en) 2002-04-08
US6077850A (en) 2000-06-20
OA11912A (en) 2006-04-11
SK5412001A3 (en) 2001-12-03
BG105513A (en) 2001-12-29
WO2000023433A1 (en) 2000-04-27
KR20010086438A (ko) 2001-09-12
NO20011940L (no) 2001-06-19
BR9914696A (pt) 2002-02-05
US20020010206A1 (en) 2002-01-24
TR200101969T2 (tr) 2001-10-22
EP1123285A1 (en) 2001-08-16
WO2000023433A8 (en) 2000-07-27
HK1040397A1 (en) 2002-06-07
HK1040397B (zh) 2004-12-10
JP2002527512A (ja) 2002-08-27
AU1092700A (en) 2000-05-08
US6492390B2 (en) 2002-12-10
ID30062A (id) 2001-11-01
CZ20011424A3 (cs) 2001-10-17
NO20011940D0 (no) 2001-04-19
MY138238A (en) 2009-05-29
CN1329607A (zh) 2002-01-02
IS5921A (is) 2001-04-18
NZ511593A (en) 2004-02-27
US7138411B2 (en) 2006-11-21
CN1150181C (zh) 2004-05-19
HUP0104316A3 (en) 2002-11-28
HUP0104316A2 (hu) 2002-04-29
EA005599B1 (ru) 2005-04-28
US20040038977A1 (en) 2004-02-26
GEP20033027B (en) 2003-07-25
IL142667A0 (en) 2002-03-10
AU767655C (en) 2004-06-17
AR024839A1 (es) 2002-10-30
AU767655B2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EA200100451A1 (ru) Замещенные аналоги бензопирана для лечения воспаления
EA199900853A1 (ru) Замещенные производные бензопирана для лечения воспалительных процессов
EA200200873A1 (ru) Новые пиперазиновые производные
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
YU56995A (sh) Soli derivata indola
EA200500249A1 (ru) Применение соединений для лечения заболевания, опосредованного vcam-1
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200201214A1 (ru) Замещенные тиоацетамиды
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
SE9802206D0 (sv) Novel compounds
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
EA199900079A1 (ru) Способ получения фенильных гетероциклов, пригодных в качестве ингибиторов цог-2
ATE288900T1 (de) Substituierte benzoylcyclohexandione
ES2188906T3 (es) Inhibidores de la enzima de conversion de la interleucina-1beta a base de sulfonamida.
EA200300597A1 (ru) Бифенилкарбоксамиды, полезные в качестве снижающих содержание липидов агентов
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
ATE297903T1 (de) Substituierte phenyluracile
SE9801494D0 (sv) Novel use
EA199700263A1 (ru) Применение производных витамина d в дерматологии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU